Beam Therapeutics Inc. (BEAM) financial statements (2022 and earlier)

Company profile

Business Address 26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:966300
Cash and cash equivalents560162
Short-term investments 140
Other undisclosed cash, cash equivalents, and short-term investments406(3)
Other undisclosed current assets3079
Total current assets:1,273308
Noncurrent Assets
Operating lease, right-of-use asset10387
Property, plant and equipment8439
Restricted cash and investments1315
Other noncurrent assets23
Total noncurrent assets:201143
TOTAL ASSETS:1,474452
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2916
Accounts payable76
Accrued liabilities102
Employee-related liabilities128
Deferred revenue86 
Debt22
Derivative instruments and hedges, liabilities4271
Other undisclosed current liabilities5313
Total current liabilities:213102
Noncurrent Liabilities
Long-term debt and lease obligation138101
Finance lease, liability35
Operating lease, liability13596
Liabilities, other than long-term debt2962
Deferred revenue262 
Other liabilities32
Business combination, contingent consideration, liability31 
Total noncurrent liabilities:434104
Total liabilities:648206
Stockholders' equity
Stockholders' equity attributable to parent827246
Common stock11
Additional paid in capital1,594643
Accumulated other comprehensive loss(0)(0)
Accumulated deficit(768)(398)
Total stockholders' equity:827246
TOTAL LIABILITIES AND EQUITY:1,474452

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
Revenues520
Gross profit:520
Operating expenses(444)(133)
Operating loss:(392)(133)
Nonoperating income (expense)22(0)
Investment income, nonoperating0(0)
Loss before gain (loss) on sale of properties:(371)(133)
Other undisclosed net loss (62)
Net loss attributable to parent:(371)(195)
Preferred stock dividends and other adjustments (1)
Net loss available to common stockholders, diluted:(371)(196)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
Net loss:(371)(195)
Comprehensive loss:(371)(195)
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(0)
Comprehensive loss, net of tax, attributable to parent:(371)(195)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: